Opioid Use Disorder
AHA provides feedback on the Drug Enforcement Administration’s (DEA’s) proposed rule for expansion of induction of buprenorphine via telemedicine encounter.
The Food and Drug Administration yesterday issued a report offering recommendations to address the opioid crisis and the role of analgesic oversight in preventing addiction, overdoses and deaths.
The share of U.S. overdose deaths involving buprenorphine did not increase after federal agencies allowed clinicians to prescribe the opioid use disorder treatment remotely, among other flexibilities during the COVID-19 public health emergency, according to a federal study reported in JAMA Network…
Nonprofit hospitals and emergency departments, including free standing EDs and Rural Emergency Hospitals, can apply through March 6 for up to $500,000 per year for up to three years to develop and implement alternatives to opioids for pain management in hospitals and ED settings, the Substance…
The AHA urges the DEA to release proposed rules for the Special Registration for Telemedicine as soon as possible. Doing so is necessary to ensure an appropriate feedback period and time for hospitals and health systems to comply with requirements.
UK HealthCare has been serving Lexington and its surrounding communities since 1962. Home to a Level I Trauma Center and a Level IV Neonatal Intensive Care Unit, UK HealthCare is committed to ensuring that every Kentuckian, no matter how sick they are, has access to quality care.
The legal principles discussed also apply to individuals with other types of substance use disorders.
In this webinar, Hazelden Betty Ford’s Stephen Delisi, MD, will examine the growing rates of substance use disorder and the impact of opioids and fentanyl on communities through his role consulting with health systems and medical professionals across the country. To focus on one health system’s…
AHA letter to Representative Donald Norcross expressing support for bipartisan legislation, the Opioid Treatment Access Act (H.R. 6279).
Nearly three-fourths of the 2.4 million U.S. adults who reported using buprenorphine in 2019 did not misuse the medication in the past 12 months, according to a National Institutes of Health study released in JAMA Network Open.